Bevacizumab Against Recurrent Retinal Detachment

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
University of Wisconsin, Madison
Study ID
NCT02192970
Phase
PHASE2
Status
Completed

Conditions

  • Proliferative Vitreoretinopathy
  • Retinal Detachment

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The investigators hypothesize that bevacizumab instilled into the vitreous after primary retinal detachment surgery will reduce the formation of proliferative vitreoretinopathy and subsequent retinal re-detachment.

Key Dates

First listed
Jul 17, 2014
Start date
Jan 21, 2015
Status verified
Mar 2021
Primary completion
Nov 11, 2019
Completion
Nov 11, 2019

Study Design

Enrollment
101 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Bevacizumab
    Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
  • No Intervention: Chart review
    Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.

Primary Outcome Measure

Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of WisconsinMadisonWisconsin53705-

Find similar trials in Madison, WI

By research site
University of Wisconsin· Madison, WI

Related Studies